V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230000920 | 230000541 | 1.64 | 68 | Palliative (P) | 2018-12-25 | 2019-01-21 | CARBOPLATIN + PACLITAXEL | 02 | N | 230024143 | SORAFENIB |
| 230000921 | 230000542 | 0 | 67.5 | Palliative (P) | 2016-03-05 | 2016-03-05 | Capecitabine + Oxaliplatin 21day | N | N | 230024225 | SORAFENIB |
| 230000922 | 230000543 | 1.81 | null | Adjuvant (A) | 2016-08-20 | 2016-09-11 | Carboplatin + Vinorelbine Oral | N | N | 230024247 | CARBOPLATIN + PACLITAXEL |
| 230000923 | 230000544 | 1.68 | 68 | Adjuvant (A) | 2016-09-13 | 2016-09-22 | CAPECITABINE + OXALIPLATIN | N | N | 230024332 | SORAFENIB |
| 230000924 | 230000545 | 1.79 | 62 | Palliative (P) | 2016-10-10 | 2016-10-21 | Capecitabine | N | N | 230024684 | TRIAL |
| 230000925 | 230000546 | 1.72 | 90.9 | Palliative (P) | 2017-03-30 | 2017-04-12 | ESPAC-4 TRIAL | 2 | N | 230024886 | SORAFENIB |
| 230000926 | 230000547 | 1.69 | 53 | Palliative (P) | 2015-07-30 | 2015-07-30 | CAPECITABINE + OXALIPLATIN | 02 | N | 230025062 | CVP R |
| 230000927 | 230000548 | 1.6 | 43.2 | Adjuvant (A) | 2017-06-26 | 2017-12-11 | Folfirinox | 2 | N | 230025109 | SORAFENIB |
| 230000928 | 230000548 | null | null | null | 2016-10-08 | 2016-10-08 | Carboplatin + Etoposide iv&po | N | null | 230025109 | DOCETAXEL |
| 230000929 | 230000548 | 1.66 | null | Palliative (P) | 2018-01-08 | 2018-01-24 | Fluorouricil + Folonic Acid (MdG) | N | N | 230025109 | CARBOPLATIN + ETOPOSIDE |
| 230000930 | 230000548 | null | null | Neo-adjuvant (N) | 2016-07-28 | 2016-08-13 | CAPECITABINE + OXALIPLATIN | N | N | 230025109 | VANDETANIB |
| 230000931 | 230000549 | null | 100 | Adjuvant (A) | 2016-02-18 | 2016-02-29 | ARISTOTLE TRIAL | N | N | 230025405 | CARBOPLATIN + ETOPOSIDE |
| 230000932 | 230000550 | 1.66 | 72.4 | Neo-adjuvant (N) | 2016-10-20 | 2016-10-27 | Sorafenib | 02 | N | 230025530 | CARBOPLATIN + PACLITAXEL |
| 230000933 | 230000550 | 1.8 | null | Neo-adjuvant (N) | 2016-08-08 | 2016-09-04 | Sorafenib | N | N | 230025530 | FLUOROURACIL + MITOMYCIN + RT |
| 230000934 | 230000551 | 1.59 | null | Adjuvant (A) | 2015-11-03 | 2015-11-12 | Oxaliplatin + Modified de Gramont | N | N | 230025600 | CISPLATIN + PACLITAXEL |
| 230000935 | 230001259 | 1.68 | 90.6 | Neo-adjuvant (N) | 2016-04-01 | 2016-04-01 | Carboplatin AUC 2 - 5 | N | Y | 230025758 | FLUOROURACIL + MITOMYCIN + RT |
| 230000936 | 230000552 | 1.63 | 52 | Palliative (P) | 2015-08-13 | 2015-09-06 | Folfirinox | 02 | N | 230025764 | OXALIPLATIN + MDG |
| 230000937 | 230000553 | 1.68 | 90.3 | Not known (9) | 2016-01-20 | 2016-02-16 | Carboplatin + Pemetrexed | N | N | 230025782 | PEMBROLIZUMAB |
| 230000938 | 230000554 | 1.62 | 50 | Adjuvant (A) | 2015-04-23 | 2015-05-01 | FLUOROURACIL + MITOMYCIN | 2 | N | 230025893 | PEMBROLIZUMAB |
| 230000939 | 230000555 | 1.65 | 51.8 | Palliative (P) | 2017-10-04 | 2017-11-01 | Capecitabine | N | N | 230025960 | TRIAL |
| 230000940 | 230000555 | null | null | Adjuvant (A) | 2015-03-01 | 2015-03-04 | VANDETANIB | N | N | 230025960 | CARBOPLATIN + PEMETREXED |
| 230000941 | 230000556 | null | null | Curative (C) | 2017-10-23 | 2017-11-06 | Oxaliplatin + Modified de Gramont | null | N | 230026072 | TRIAL |
| 230000942 | 230000557 | 1.73 | 86.8 | Adjuvant (A) | null | 2016-10-03 | CAPECITABINE + OXALIPLATIN | 2 | N | 230026218 | CHOP R |
| 230000943 | 230000557 | 1.55 | 42.2 | Adjuvant (A) | 2017-11-10 | 2017-11-28 | CARBOPLATIN + ETOPOSIDE | N | N | 230026218 | CHOP R |
| 230000944 | 230000558 | 1.71 | 93 | Adjuvant (A) | 2015-05-16 | 2015-06-16 | CAPECITABINE + IRINOTECAN | 02 | null | 230026392 | FLUOROURACIL |
| 230000945 | 230000558 | 1.87 | 91.9 | Palliative (P) | 2012-11-04 | 2013-09-24 | Capecitabine 35days + RT | N | N | 230026392 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 230000946 | 230000558 | 0 | 73.2 | Neo-adjuvant (N) | 2016-05-18 | 2016-06-06 | FLUOROURACIL | N | N | 230026392 | CISPLATIN + DOXORUBICIN |
| 230000947 | 230000558 | 1.51 | 60.7 | Adjuvant (A) | 2018-02-07 | 2018-02-07 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | null | 230026392 | TRIAL |
| 230000948 | 230000559 | 1.64 | null | Neo-adjuvant (N) | 2017-06-11 | 2017-06-24 | CARBOPLATIN + PACLITAXEL | null | N | 230026568 | CISPLATIN + DOCETAXEL |
| 230000949 | 230000560 | 1.55 | 56.6 | Adjuvant (A) | 2015-02-15 | 2015-02-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 230026577 | GEMCITABINE |
| 230000950 | 230000561 | 1.68 | 76.8 | Neo-adjuvant (N) | 2017-06-09 | 2017-06-09 | Oxaliplatin + Modified de Gramont | 02 | null | 230026596 | CARBOPLATIN + PACLITAXEL |
| 230000951 | 230000562 | 1.6 | 63.2 | Adjuvant (A) | 2016-11-12 | 2016-11-12 | CAP + RT | N | N | 230026626 | TRIAL |
| 230000952 | 230000563 | 1.5 | 55.4 | Neo-adjuvant (N) | 2016-12-16 | 2016-12-21 | OXALIPLATIN + MDG + PANITUMUMAB | 2 | N | 230026769 | TEMOZOLOMIDE |
| 230000953 | 230000564 | 1.63 | 61.4 | Adjuvant (A) | 2016-07-09 | 2016-08-05 | Capecitabine + Oxaliplatin 21day | 02 | Y | 230026800 | FLUOROURACIL + MITOMYCIN + RT |
| 230000954 | 230001263 | 1.74 | null | Palliative (P) | 2016-10-06 | 2016-10-07 | CHOP R - 21 days | N | N | 230026820 | MITOMYCIN INTRAVESICULAR |
| 230000955 | 230001263 | 1.55 | 64.5 | Adjuvant (A) | 2015-07-02 | 2015-07-02 | CAPECITABINE + RT | N | N | 230026820 | VANDETANIB |
| 230000956 | 230000565 | 1.52 | 54.4 | Neo-adjuvant (N) | 2015-04-21 | 2015-05-04 | FLUOROURACIL + MITOMYCIN + RT | 2 | Y | 230027019 | BENDAMUSTINE + RITUXIMAB |
| 230000957 | 230001264 | 1.62 | 73.9 | Curative (C) | 2015-09-10 | 2015-09-30 | Trastuzumab Subcutaneous | 2 | Y | 230027082 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 230000958 | 230000566 | 1.6 | 72 | Curative (C) | 2017-05-03 | 2017-05-11 | Capecitabine + Oxaliplatin 21day | 2 | N | 230027175 | CHOP R |
| 230000959 | 230000567 | 1.68 | 72 | Palliative (P) | 2017-07-04 | 2017-07-08 | FLUOROURACIL | 02 | N | 230027242 | VANDETANIB |
| 230000960 | 230001265 | 1.54 | 49.1 | Adjuvant (A) | 2017-09-24 | 2017-10-09 | ARISTOTLE TRIAL | 02 | N | 230027394 | CAPECITABINE |
| 230000961 | 230000568 | 1.6 | 59.4 | Adjuvant (A) | null | 2016-06-20 | FLUOROURACIL | null | N | 230027403 | CARBOPLATIN + PEMETREXED |
| 230000962 | 230000568 | 0 | null | Curative (C) | 2017-03-14 | 2017-03-22 | Carboplatin + Etoposide IV 3 day | N | N | 230027403 | CARBOPLATIN + ETOPOSIDE |
| 230000963 | 230000569 | 1.68 | null | Adjuvant (A) | 2014-03-10 | 2014-03-19 | CISPLATIN + RT | N | N | 230027421 | IRINOTECAN + MDG |
| 230000964 | 230000570 | 1.63 | 66 | Adjuvant (A) | 2016-11-22 | 2016-12-04 | CARBOPLATIN + PACLITAXEL | 02 | N | 230027443 | VANDETANIB |
| 230000965 | 230000571 | 1.6 | 73.8 | Palliative (P) | 2018-10-27 | 2018-11-07 | CTD | 2 | N | 230027529 | SORAFENIB |
| 230000966 | 230000572 | 0 | 59.2 | Adjuvant (A) | 2016-10-21 | 2017-10-29 | Cyclophosphamide + Docetaxel | N | N | 230027620 | CISPLATIN + FLUOROURACIL + RT |
| 230000967 | 230000572 | 1.66 | 112.1 | Curative (C) | 2016-04-21 | 2016-04-21 | Capecitabine + Oxaliplatin 21day | N | Y | 230027620 | CISPLATIN + DOCETAXEL |
| 230000968 | 230000573 | 1.59 | 109 | Palliative (P) | 2018-06-25 | 2018-06-26 | Oxaliplatin + Modified de Gramont | N | N | 230028110 | PACLITAXEL |
| 230000969 | 230000574 | 1.64 | 79 | Curative (C) | 2018-12-08 | 2018-12-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | Y | 230028182 | FLUOROURACIL + MITOMYCIN + RT |